XTLB Stock Overview

A biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases in Israel. More details

XTLB fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	3/6
Dividends	0/6

Rewards

Earnings have grown 11.1% per year over the past 5 years

Risk Analysis

Highly volatile share price over the past 3 months compared to the IL market

Makes less than USD$1m in revenue ($46K)

Shareholders have been substantially diluted in the past year

Does not have a meaningful market cap (₪52M)

My Notes

Capture your thoughts, links and company narrative

XTL Biopharmaceuticals Ltd. Competitors

BioLineRx

TASE:BLRX

₪79.0m

PlantArc Bio

TASE:PLNT

₪7.7m

Grace Breeding

TASE:GRAC

₪66.6m

Can-Fite BioPharma

TASE:CANF

₪59.8m

Price History & Performance

Summary of share price highs, lows and changes for XTL Biopharmaceuticals
Historical stock prices
Current Share Price	₪0.059
52 Week High	₪0.17
52 Week Low	₪0.031
Beta	1.05
1 Month Change	15.69%
3 Month Change	-30.59%
1 Year Change	68.57%
3 Year Change	-35.16%
5 Year Change	22.92%
Change since IPO	-99.75%

Recent updates

We're Interested To See How XTL Biopharmaceuticals (TLV:XTLB) Uses Its Cash Hoard To Grow

Jul 02

Shareholder Returns

	XTLB	IL Biotechs	IL Market
7D	-11.9%	-2.4%	3.2%
1Y	68.6%	-20.9%	31.5%

Return vs Industry: XTLB exceeded the IL Biotechs industry which returned -20.9% over the past year.

Return vs Market: XTLB exceeded the IL Market which returned 31.5% over the past year.

Price Volatility

Is XTLB's price volatile compared to industry and market?
XTLB volatility
XTLB Average Weekly Movement	12.2%
Biotechs Industry Average Movement	10.7%
Market Average Movement	4.4%
10% most volatile stocks in IL Market	8.9%
10% least volatile stocks in IL Market	3.1%

Stable Share Price: XTLB's share price has been volatile over the past 3 months compared to the IL market.

Volatility Over Time: XTLB's weekly volatility has decreased from 23% to 12% over the past year, but is still higher than 75% of IL stocks.

About the Company

Founded	Employees	CEO	Website
1993	n/a	Shlomo Shalev	www.xtlbio.com

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren’s syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications.

XTL Biopharmaceuticals Ltd. Fundamentals Summary

How do XTL Biopharmaceuticals's earnings and revenue compare to its market cap?
XTLB fundamental statistics
Market cap	₪52.00m
Earnings (TTM)	-₪3.77m
Revenue (TTM)	₪164.04k

317.0x

P/S Ratio

-13.8x

P/E Ratio

Is XTLB overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
XTLB income statement (TTM)
Revenue	US$46.00k
Cost of Revenue	US$0
Gross Profit	US$46.00k
Other Expenses	US$1.10m
Earnings	-US$1.06m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.0012
Gross Margin	100.00%
Net Profit Margin	-2,295.65%
Debt/Equity Ratio	0%

How did XTLB perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/18 03:05
End of Day Share Price	2025/01/16 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

XTL Biopharmaceuticals Ltd. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Swayampakula Ramakanth	H.C. Wainwright & Co.